FindTrial
Sign In

Exploring the efficacy and safety of brexpiprazole for behavioral and psychological symptoms of Alzheimer's disease in clinical settings

Exploring the efficacy and safety of brexpiprazole for behavioral and psychological symptoms of Alzheimer's disease in clinical settings - Exploring the efficacy and safety of brexpiprazole for behavioral and psychological symptoms of Alzheimer's disease in clinical settings

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000056887
Enrollment
50
Registered
2025-01-31
Start date
2025-02-03
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alzheimer&#39

Interventions

Administration of brexpiprazole

Sponsors

Kurita hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Meets the DSM-5 diagnostic criteria for Alzheimer's disease 2. MMSE score is 1-22 3. NPI-Q agitation/aggression score is 2 or higher 4. Takes Yokukansan or antipsychotics (CP equivalent: 200mg or less) 5. Concomitant use of anti-dementia drugs, sleeping pills, etc. is permitted under certain conditions

Exclusion criteria

Exclusion criteria: 1, Comorbid dementia other than Alzheimer's disease. 2, Comorbid schizophrenia, mood disorder, anxiety disorder, drug/substance addiction, delirium, or personality disorder. 3, Serious physical illnesses such as cerebrovascular disease, renal dysfunction, and neurological disease. 4, The principal investigator or attending physician determines that the subject is unsuitable for the study.

Design outcomes

Primary

MeasureTime frame
Change in NPI-Q total score before and after administration of brexpiprazole—

Secondary

MeasureTime frame
Changes in NPI-Q subscores and CGI-S before and after brexpiprazole administration—

Countries

Japan

Contacts

Public ContactAkira Tanaka

Kurita hospital psychiatry

a-tanaka@kuritahp.or.jp0262261311

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026